E-DICE-R applied to multi-omics discovery.
E-DICE-R is a live, authority-governed AI platform running cancer biomarker discovery workflows on public multi-omics data. Two candidates were identified and replicated in an independent cohort. A deeper analysis has since revealed an entire unstudied ciliary pathway — and a convergent evidence signal pointing toward invasive biology.
SPIE 2026 — Defense + Commercial Sensing.
E-DICE-R's foundational research is positioned through SPIE 2026 and helps frame the platform's governance architecture and discovery methodology.
2026
- Authority computation and deterministic execution control
- Governed optimization (EGAO) for multi-step workflows
- Policy enforcement without human override
- Six molecular evidence streams under governance control
- TCGA prostate cancer dataset — 19,010 genes
- Zero human guidance in candidate selection
- Classical + quantum-inspired + quantum coordination
- Integrity control and emergence governance
- Federated execution with trust constraints
- 100% reproducibility across tested dataset cohorts
- 48/48 safety tests passing on live platform
- Public TCGA data — no proprietary data used
A prostate cancer signal no prior research had published.
E-DICE-R's governed workflow screened 19,010 genes across six evidence types and surfaced a statistically strong signal with no prior cancer publications found during review.
Strong stats. Perfect reproducibility. Zero prior publications.
This is what governance-first AI can do — surface biology that conventional approaches miss, from public data alone, with no human candidate guidance and full execution control throughout.
After replication, a broader pattern. An entire pathway unstudied.
MSKCC replication confirmed both candidates. A systematic literature search then revealed something more significant: This candidate's entire protein family — 8 canonical ciliary motor genes — has no published prostate cancer research. The second candidate overexpresses without its 10 known interaction partners. The lead candidate and its pathway partner converge through independent evidence paths toward cytoskeletal biology.
Candidate screening — TCGA
Both genes replicated independently
8 genes, 0 papers
Convergent paths, cytoskeletal signal
- Moonlighting: possible non-ciliary function in prostate tumor cells
- Pathway disruption: ciliary signaling dysregulated in a cancer-specific way
- Biological role uncharacterized — testable in wet lab
- Points toward cytoskeletal regulation and cell motility biology
- Mechanistically linked to invasion and metastasis pathways
- Most actionable functional lead from the current analysis
What these signals may suggest — and what they do not yet prove
How the governed workflow found the lead candidate.
The E-DICE-R governance layer executed an autonomous multi-omics screen under quality gates, without pre-selected hypotheses or manual steering.
We claim the method that identifies, validates, and governs its use.
E-DICE-R is a proprietary governed multi-omics pipeline. The IP is the structured, reproducible, authority-scored process — not the gene. PRR36 is a result produced by that method. The method is what we sell. The method is what we protect.
The method and process
E-DICE-R converts multi-omics discovery into a governed, repeatable decision system for identifying and prioritizing therapeutic and diagnostic targets. The invention defines a structured pipeline that ingests heterogeneous data, applies authority-based scoring and validation, and produces ranked, auditable outputs.
- Method: defined pipeline for ingesting, processing, scoring, and ranking targets from multi-omics data
- Decision engine: authority-based filtering, evidence weighting, and cross-cohort validation
- Outputs: ranked candidates for diagnostics, biomarkers, and therapeutic targeting
- System: architecture enforcing reproducibility, auditability, and deterministic workflows
- Pharma linkage: integration into target selection, validation, and drug development workflows
What our method found
An early governed discovery run surfaced the lead candidate as a statistically strong exploratory find from a 19,010-gene prostate cancer screen — independently replicated in the MSKCC cohort (GSE21034). The full methodology, signal details, and interpretation scope are documented in the discovery summary.
View discovery summary →E-DICE-R turns multi-omics discovery into a governed decision system.
The invention is defined across three interlocking claims — method, system, and pharma workflow — each protecting a distinct layer of the pipeline. Together they form a complete, defensible IP position around the governed discovery process.
- Structured target-identification pipeline
- Evidence weighting and cross-cohort validation
- Ranked outputs for diagnostics, biomarkers, and therapeutic targeting
- Reproducibility and auditability by design
- Deterministic workflows and evidence traceability
- Architecture-level protection around the ranking engine
- Structured evidence packages for portfolio review
- Target selection and validation tracking
- Application-level use of identified targets
E-DICE-Edge SDK exposes the molecular governance layer of E-DICE-R and E-DICE-R as a deployable integration for external pipelines. Through E-DICE-Edge Partner Vault, partners can apply authority-based scoring, non-compensating validation gates, and deterministic audit workflows directly to their own datasets.